Catabasis Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>CP</div>
CATB -- USA Stock  

USD 2.93  0.06  2.09%

Catabasis Pharmaceuticals Average Equity is projected to increase significantly based on the last few years of reporting. The past year's Average Equity was at 48.08 Million. The current year Invested Capital is expected to grow to about 36.1 M, whereas Average Assets are forecasted to decline to about 52.1 M. While many traders today are more concerned about the preservation of capital over market returns, Catabasis Pharmaceuticals could be one exception. We will evaluate why recent Catabasis Pharmaceuticals price moves suggest a bounce in March. This post is to show some fundamental factors affecting Catabasis Pharmaceuticals' products and services. I will also drop some light on how it may impact the investing outlook for Catabasis Pharmaceuticals in March.
Published over a month ago
View all stories for Catabasis Pharma | View All Stories
Catabasis Pharmaceuticals (NASDAQ:CATB) continues to rise
About 41.0% of Catabasis Pharmaceuticals shares are held by institutions such as insurance companies. Insiders ownership of Catabasis Pharmaceuticals refers to the amount of Catabasis Pharmaceuticals equity owned by Catabasis officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Catabasis, including its current ownership diagnostics.

How important is Catabasis Pharma's Liquidity

Catabasis Pharma financial leverage refers to using borrowed capital as a funding source to finance Catabasis Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Catabasis Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Catabasis Pharma's total debt and its cash.

How Catabasis utilizes its cash?

To perform a cash flow analysis of Catabasis Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Catabasis Pharma is receiving and how much cash it distributes out in a given period. The Catabasis Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Catabasis Pharma Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (23.91 Million)

Acquisition by Callori Fred of 1617 shares of Catabasis Pharma subject to Rule 16b-3

Legal trades by Catabasis Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Catabasis insider trading alert for grant of series x convertible preferred stock by Callori Fred, the corporate stakeholder, on 3rd of February 2021. This event was filed by Catabasis Pharmaceuticals with SEC on 2021-02-03. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Catabasis Pharma

Catabasis Pharmaceuticals holds a total of twenty million eighty thousand outstanding shares. 30% of Catabasis Pharmaceuticals outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Breakdown

Retail Investors
59.23%
Institutions
40.64%
Retail Investors59.23
Insiders0.13
Institutions40.64

Will Catabasis Pharmaceuticals current rise continue?

Current mean deviation is at 5.03. Catabasis Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Catabasis Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Catabasis Pharmaceuticals volatility.

The Bottom Line

Whereas few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Catabasis Pharmaceuticals may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor exit any shares of Catabasis Pharmaceuticals at this time. The Catabasis Pharmaceuticals risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Catabasis Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Catabasis Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com